Modulation of TCA cycle enzymes and electron transport chain systems in experimental lung cancer

P Senthilnathan1, R Padmavathi, V Magesh

  • 1Department of Medical Biochemistry, Dr. ALM Postgraduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai 600 113, India. senthilnpm@rediffmail.com

Life Sciences
|September 7, 2005
PubMed

Insights

This study investigated Withania somnifera and paclitaxel for lung cancer. The combination therapy normalized key metabolic enzymes, showing promise for lung cancer treatment.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Lung cancer is a major global health concern.
  • Benzo(a)pyrene is a known carcinogen that can induce lung cancer in animal models.
  • Tricarboxylic acid (TCA) cycle and electron transport chain are crucial for cellular energy production and can be affected by cancer.

Purpose of the Study:

  • To investigate the modulatory effects of Withania somnifera (Ashwagandha) in combination with paclitaxel on key enzymes of the TCA cycle and electron transport chain complexes in a mouse model of lung cancer.
  • To evaluate the potential of this combination as a chemotherapeutic agent for lung cancer.

Main Methods:

  • Lung cancer was induced in Swiss albino mice using benzo(a)pyrene.
  • Mice were treated with Withania somnifera and paclitaxel, individually and in combination.
  • Activities of key TCA cycle enzymes (isocitrate dehydrogenase, succinate dehydrogenase, malate dehydrogenase, alpha-ketoglutarate dehydrogenase) and electron transport chain complexes were measured in lung tissue.
  • Biochemical parameters were compared between control, cancer-bearing, and treatment groups.

Main Results:

  • Benzo(a)pyrene-induced lung cancer led to decreased activities of key TCA cycle enzymes in the lungs.
  • Administration of Withania somnifera along with paclitaxel significantly inclined the activities of these enzymes towards normal control levels.
  • The combination therapy demonstrated a chemotherapeutic effect, improving energy production efficiency indicated by mitochondrial enzyme and electron transport complex activities.

Conclusions:

  • The combination of Withania somnifera and paclitaxel exhibits a significant chemotherapeutic effect against benzo(a)pyrene-induced lung cancer in mice.
  • This combination therapy normalizes the biochemical alterations in TCA cycle enzymes and electron transport chain complexes, suggesting improved cellular energy metabolism.
  • Withania somnifera combined with paclitaxel represents a promising chemotherapeutic strategy for lung cancer treatment.